Ortho RTi Confirms Timeline to Initiate Human Clinical Program in Rotator Cuff Repair

Ortho Regenerative Technologies (Ortho RTi) announced that following a formal meeting with FDA, the company can submit its Investigational New Drug (IND) for Ortho-R biopolymer for rotator cuff repair while completing its pivotal study, and will initiate a human clinical program by year-end.

The proprietary biopolymer has been designed to...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us